These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31070988)

  • 21. Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.
    Heine SJ; Diaz-McNair J; Martinez-Becerra FJ; Choudhari SP; Clements JD; Picking WL; Pasetti MF
    Vaccine; 2013 Jun; 31(28):2919-29. PubMed ID: 23644075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
    McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL
    Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding.
    Venkatesan MM; Ballou C; Barnoy S; McNeal M; El-Khorazaty J; Frenck R; Baqar S
    PLoS One; 2021; 16(11):e0259361. PubMed ID: 34793505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of an Aotus nancymaae model for Shigella Vaccine immunogenicity and efficacy studies.
    Gregory M; Kaminski RW; Lugo-Roman LA; Galvez Carrillo H; Tilley DH; Baldeviano C; Simons MP; Reynolds ND; Ranallo RT; Suvarnapunya AE; Venkatesan MM; Oaks EV
    Infect Immun; 2014 May; 82(5):2027-36. PubMed ID: 24595138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly homogenous tri-acylated S-LPS acts as a novel clinically applicable vaccine against Shigella flexneri 2a infection.
    Ledov VA; Golovina ME; Markina AA; Knirel YA; L'vov VL; Kovalchuk AL; Aparin PG
    Vaccine; 2019 Feb; 37(8):1062-1072. PubMed ID: 30670300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
    Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1.
    Pozsgay V; Chu C; Pannell L; Wolfe J; Robbins JB; Schneerson R
    Proc Natl Acad Sci U S A; 1999 Apr; 96(9):5194-7. PubMed ID: 10220442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development.
    Mani S; Toapanta FR; McArthur MA; Qadri F; Svennerholm AM; Devriendt B; Phalipon A; Cohen D; Sztein MB
    Vaccine; 2019 Aug; 37(34):4787-4793. PubMed ID: 31230883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model.
    Barry EM; Wang J; Wu T; Davis T; Levine MM
    Vaccine; 2006 May; 24(18):3727-34. PubMed ID: 16169130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inactivated and subunit vaccines to prevent shigellosis.
    Kaminski RW; Oaks EV
    Expert Rev Vaccines; 2009 Dec; 8(12):1693-704. PubMed ID: 19943764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
    Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.
    Passwell JH; Harlev E; Ashkenazi S; Chu C; Miron D; Ramon R; Farzan N; Shiloach J; Bryla DA; Majadly F; Roberson R; Robbins JB; Schneerson R
    Infect Immun; 2001 Mar; 69(3):1351-7. PubMed ID: 11179298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.
    Chakraborty S; Harro C; DeNearing B; Bream J; Bauers N; Dally L; Flores J; Van de Verg L; Sack DA; Walker R
    Clin Vaccine Immunol; 2016 Apr; 23(4):315-25. PubMed ID: 26865592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of recombinant vaccine candidate molecule against Shigella infection.
    Chitradevi STS; Kaur G; Sivaramakrishna U; Singh D; Bansal A
    Vaccine; 2016 Oct; 34(44):5376-5383. PubMed ID: 27591952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination With Mouse Dendritic Cells Loaded With an IpaD-IpaB Fusion Provides Protection Against Shigellosis.
    Arizmendi O; Kumar P; Zheng Q; Stewart JP; Picking WD; Picking W; Martinez-Becerra FJ
    Front Immunol; 2019; 10():192. PubMed ID: 30800131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective immunity by oral immunization with heat-killed Shigella strains in a guinea pig colitis model.
    Barman S; Koley H; Ramamurthy T; Chakrabarti MK; Shinoda S; Nair GB; Takeda Y
    Microbiol Immunol; 2013 Nov; 57(11):762-71. PubMed ID: 24033533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.
    Cohen D; Ashkenazi S; Green MS; Gdalevich M; Robin G; Slepon R; Yavzori M; Orr N; Block C; Ashkenazi I; Shemer J; Taylor DN; Hale TL; Sadoff JC; Pavliakova D; Schneerson R; Robbins JB
    Lancet; 1997 Jan; 349(9046):155-9. PubMed ID: 9111538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shigella vaccine development: prospective animal models and current status.
    Kim YJ; Yeo SG; Park JH; Ko HJ
    Curr Pharm Biotechnol; 2013; 14(10):903-12. PubMed ID: 24372251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.
    DeLaine BC; Wu T; Grassel CL; Shimanovich A; Pasetti MF; Levine MM; Barry EM
    Pathog Dis; 2016 Jul; 74(5):. PubMed ID: 27106253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.